Impact of Comorbidity on Survival Among Men With Localized Prostate Cancer
- 1 April 2011
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (10), 1335-1341
- https://doi.org/10.1200/jco.2010.31.2330
Abstract
To provide patients and clinicians more accurate estimates of comorbidity-specific survival stratified by patient age, tumor stage, and tumor grade. We conducted a 10-year competing risk analysis of 19,639 men 66 years of age and older identified by the Surveillance, Epidemiology, and End Results (SEER) program linked to Medicare program files. All men were diagnosed with localized prostate cancer and received no surgery or radiation within 180 days of diagnosis. The analysis was stratified by tumor grade and stage and by age and comorbidity at diagnosis classified using the Charlson comorbidity index. Underlying causes of death were obtained from SEER. During the first 10 years after diagnosis, men with moderately and poorly differentiated prostate cancer were more likely to die from causes other than their disease. Depending on patient age, Gleason score, and number of comorbidities present at diagnosis, 5-year overall mortality rates for men with stage T1c disease ranged from 11.7% (95% CI, 10.2% to 13.1%) to 65.7% (95% CI, 55.9% to 70.1%), and prostate cancer–specific mortality rates ranged from 1.1% (95% CI, 0.0% to 2.7%) to 16.3% (95% CI, 13.8% to 19.4%). Ten-year overall mortality rates ranged from 28.8% (95% CI, 25.3% to 32.6%) to 94.3% (95% CI, 87.4% to 100%), and prostate cancer–specific mortality rates ranged from 2.0% (95% CI, 0.0% to 5.3%) to 27.5% (95% CI, 21.5% to 36.5%). Patients and clinicians should consider using comorbidity-specific data to estimate the threat posed by newly diagnosed localized prostate cancer and the threat posed by competing medical hazards.Keywords
This publication has 28 references indexed in Scilit:
- Outcomes of Localized Prostate Cancer Following Conservative ManagementJAMA, 2009
- Patients' Survival Expectations before Localized Prostate Cancer Treatment by Treatment StatusThe Journal of the American Board of Family Medicine, 2009
- Mortality Results from a Randomized Prostate-Cancer Screening TrialThe New England Journal of Medicine, 2009
- Screening and Prostate-Cancer Mortality in a Randomized European StudyThe New England Journal of Medicine, 2009
- A Nomogram Predicting 10-Year Life Expectancy in Candidates for Radical Prostatectomy or Radiotherapy for Prostate CancerJournal of Clinical Oncology, 2007
- Tutorial in biostatistics: competing risks and multi‐state modelsStatistics in Medicine, 2006
- Predicting Life Expectancy in Men With Clinically Localized Prostate CancerJournal of Urology, 2006
- LONG-TERM SURVIVAL PROBABILITY IN MEN WITH CLINICALLY LOCALIZED PROSTATE CANCER: A CASE-CONTROL, PROPENSITY MODELING STUDY STRATIFIED BY RACE, AGE, TREATMENT AND COMORBIDITIESJournal of Urology, 2004
- Determining Cause of Death in Prostate Cancer: Are Death Certificates Valid?JNCI Journal of the National Cancer Institute, 2001
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987